Elsevier

Annals of Oncology

Volume 8, Issue 5, May 1997, Pages 500-502
Annals of Oncology

Short reports
A phase II study of raltitrexed (‘Tomudex’*) in patients with hepatocellular carcinoma

https://doi.org/10.1023/A:1008249328792Get rights and content
Under an Elsevier user license
open archive

Keywords

chemotherapy
hepatocellular carcinoma
raltitrexed
‘Tomudex’
treatment outcome

Cited by (0)

*

‘Tomudex’ is a trade mark, the property of Zeneca Limited.